Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.36 |
| ▸ | DUT | P33316 | 3/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 7/20 | 0.32 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.32 |
| ▸ | TOP2A | P11388 | 1/20 | 0.32 |
| ▸ | PDCD1LG2 | Q9BQ51 | 2/20 | 0.31 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20305038 | 1.00 | IRAK4 (0.36) | IRAK4DUTS1PR1FKBP1ATOP2A | |
| SCHEMBL21803491 | 1.00 | IRAK4 (0.36) | IRAK4DUTS1PR1FKBP1ATOP2A | |
| SCHEMBL2212134 | 0.84 | DUT (0.33) | DUTFKBP1ATOP2A | |
| SCHEMBL20304422 | 0.78 | IRAK4 (0.37) | IRAK4DUTTOP2A | |
| SCHEMBL16043809 | 0.78 | SMYD2 (0.43) | IRAK4S1PR1PDCD1LG2CD274 | |
| SCHEMBL15209214 | 0.78 | SMYD2 (0.43) | IRAK4S1PR1PDCD1LG2CD274 | |
| SCHEMBL2365710 | 0.75 | — | — | |
| SCHEMBL2365703 | 0.75 | — | — | |
| SCHEMBL15209640 | 0.75 | — | — | |
| SCHEMBL211169 | 0.74 | IRAK4 (0.37) | IRAK4DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11084829-B2 | Ubiquitin-specific-processing protease 7 (USP7) modulators and uses thereof | RAPT THERAPEUTICS, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| WO-2020068600-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | RAPT THERAPEUTICS, INC. (US) | 2020-04-02 | — | — | WO | disclosed |
| US-20200095260-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | RAPT THERAPEUTICS, INC. | 2020-03-26 | — | — | US | disclosed |
| EP-1586564-B1 | 8-AZAPROSTAGLANDIN DERIVATIVES AND MEDICINAL USES THEREOF | ONO PHARMACEUTICAL CO (JP) | 2012-11-28 | — | — | EP | disclosed |
| US-20080033033-A1 | 8-AZAPROSTAGLANDIN DERIVATIVES AND MEDICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. | 2008-02-07 | — | — | US | disclosed |
| US-7256211-B1 | 8-azaprostaglandin derivatives and medical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-08-14 | — | — | US | disclosed |
| EP-1586564-A1 | 8-AZAPROSTAGLANDIN DERIVATIVES AND MEDICINAL USES THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200095260-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | USP7, SENP7, USP8 | IRAK4 2507/4885DUT 2435/4885S1PR1 4683/4885 |
| US-20080033033-A1 | 8-AZAPROSTAGLANDIN DERIVATIVES AND MEDICAL USE THEREOF | HPGDS, PTGIS, PTGER4 | IRAK4 952/4885DUT 2147/4885S1PR1 1825/4885 |
| US-11084829-B2 | Ubiquitin-specific-processing protease 7 (USP7) modulators and uses thereof | USP7, SENP7, USP8 | IRAK4 2507/4885DUT 2435/4885S1PR1 4683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.